Monoclonal Antibody Therapeutics Market Report 2025 (Global Edition)

Global Monoclonal Antibody Therapeutics Market Report 2025 Market Size Split by Source type (Murine, Chimeric, Humanized, Human), by Application (Oncology, Autoimmune Diseases, Infectious Diseases, Ne...

Monoclonal Antibody Therapeutics Market Report Description

We have various report editions of Monoclonal Antibody Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive landscape – Monoclonal Antibody Therapeutics market

Antibody therapy is a targeted treatment method that uses monoclonal antibodies to manage diseases like cancer, infectious diseases, and autoimmune disorders. These antibodies bind to specific molecules on cell surfaces, triggering immune responses that eliminate or inhibit abnormal cell growth. This approach is promising in medical intervention and personalized medicine. Antibodies are widely used in oncology, neurology, autoimmunology, and cardiology. The global antibody market is expected to grow as chronic diseases become more prevalent. Technological developments in antibody-based therapeutics target tumor antigens and increase immune cells' anti-tumor capabilities. The market for antibody therapy is also expected to grow due to rapid technological innovation and product development in the cancer treatment industry. Upcoming market players are focusing on expanding their research and business scope through financing rounds. Top companies in the antibodies market are advancing their research and fast-tracking the development of new antibodies to gain a competitive advantage.

Top Companies Market Share in Monoclonal Antibody Therapeutics Industry: (In no particular order of Rank)

• Novartis AG
• Pfizer Inc
• GlaxoSmithKline plc
• Amgen Inc.
• Merck & Co.
• Inc.
• Daiichi Sankyo Company
• Limited
• Abbott Laboratories
• AstraZeneca plc
• Eli Lilly And Company
• Johnson & Johnson Services
• Inc.
• Bayer AG
• Bristol Myers Squibb
• F. Hoffman-La Roche Ltd.
• Viatris Inc.
• Biogen Inc.
• Thermo Fisher Scientific
• Inc.
• Novo Nordisk A/S
• Sanofi S.A.
• Merck KGaA
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Which region dominates the market in 2024?

North America is currently dominating the global Monoclonal Antibody Therapeutics market and also has a notable expansion in the Monoclonal Antibody Therapeutics market. North America held a market share of around xx% and xx million of the global antibody revenue in 2023, making it the largest market in the world. The largest market is anticipated to be in North America. as a result of major players' growing efforts in the creation of novel antibody treatments. More clinical trials have also been carried out as a result of the region's strong need for targeted pharmaceuticals, which has benefited the market as a whole. Furthermore, it is projected that the region's high healthcare spending and sophisticated healthcare infrastructure will support regional market expansion. The rising incidence of cancer in North America presents a lucrative opportunity for the market.

Which Region is Expanding at the Fastest CAGR?

The Asia-Pacific Monoclonal Antibody Therapeutics market is expanding quickly due to rising consumer buying power and strong demand brought on by growing product advantages. Between 2024 and 2031, the Asia-Pacific market is anticipated to develop at the quickest compound annual growth rate (CAGR) because of the region's aging population and the illnesses that are associated with it. Furthermore, it is expected that the discovery and manufacture of antibodies in China will grow quickly due to increased government funding for medication development and growing public awareness of illnesses like rheumatoid arthritis, cancer, and infections. Because of its growing emphasis on healthcare, huge patient pool for mAb cancer therapies, and rising disposable income, the Asia Pacific region is expected to develop at the quickest pace of xx% throughout the projection period. It is projected that nations like China and India will favorably influence mAb research and development prospects and present enticing funding options for clinical research. 

The current report Scope analyzes Monoclonal Antibody Therapeutics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Monoclonal Antibody Therapeutics Market Analysis

Monoclonal Antibody Therapeutics Market

• Murine
• Chimeric
• Humanized
• Human

According to cognitive market research, humanized segment dominates the market. Humanized antibodies have a majority of human sequences, with only a small portion of mouse sequences in the complementarity-determining regions (CDRs). Humanizing reduces the immunogenicity associated with murine mAbs. Humanized mAbs are named using the suffix “-zumab” at the end of the generic name. For example, “trastuzumab” is a humanized antibody used in the treatment of HER2-positive breast cancer.  In general, humanized monoclonal antibodies generate lower levels of ADAs compared to chimeric monoclonal antibodies, although the incidence of ADAs is not eliminated. Additionally, humanization of monoclonal antibodies often has the unintended consequence of altering monoclonal antibody specificity.  Over time, the humanization process of mouse-derived antibodies has become much more sophisticated, with several companies now performing in silico optimization of CDRs for T-cell epitope avoidance to reduce immunogenicity.  Newer transgenic mice that have a fuller complement of human antibody genes are also being used to develop a new generation of fully human monoclonal antibodies.
•    For instance, Humanized monoclonal antibodies, such as Zenapax (daclizumab, approved in 1997) are an extension of the chimera strategy in which all regions of the mouse antibody are replaced with human counterparts except for the complementarity-determining regions (CDRs, i.e., the amino acids that make direct contact with the antigen).
(Source:https://www.allucent.com/resources/blog/monoclonal-antibodies-past-present-and-future)

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Monoclonal Antibody Therapeutics Industry. Request a Free Sample PDF!

Monoclonal Antibody Therapeutics Market

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Neurological Diseases
• Others

According to cognitive market research, Oncology segment dominates the market. Monoclonal antibody-based immunotherapy is now considered to be a main component of cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies possess a diverse set of clinically relevant mechanisms of action. In addition, antibodies can directly target tumor cells while simultaneously promoting the induction of long-lasting anti-tumor immune responses. The multifaceted properties of antibodies as a therapeutic platform have led to the development of new cancer treatment strategies that will have major impacts on cancer care. This review focuses on the known mechanisms of action, current clinical applications for the treatment of cancer, and mechanisms of resistance to monoclonal antibody therapy. We further discuss how monoclonal antibody-based strategies have moved towards enhancing anti-tumor immune responses by targeting immune cells instead of tumor antigens as well as some of the current combination therapies. The main direct mechanism by which many antibodies induce tumor cell death is the blockade of growth factor receptor signaling. Pro-tumor growth and survival signaling are perturbed when mAbs bind their target growth factor receptors and manipulate their activation state or block ligand binding. 
•    For instance,  epidermal growth factor receptor (EGFR) is overexpressed by many different cancers, and signaling via EGFR leads to tumor cell proliferation, migration, and invasion. Cetuximab, which is an anti-EGFR mAb, induces apoptosis in tumor cells by blocking ligand binding and receptor dimerization
(Source:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551545/)

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Monoclonal Antibody Therapeutics Production Type Segment Analysis

According to cognitive market research, In-Vitro segment dominates the market. The In-vitro antibody production method involves the use of hybridoma cells, mammalian cell culture, or recombinant technology to produce large quantities of monoclonal or polyclonal antibodies. Different commercial in vitro systems meet the different needs and requirements of users. The many systems can be split into two types; single-compartment systems that allow only low-density cell culture, and double-compartment systems that allow high-density cell culture, which results in increased mAb concentration. There is also the distinction between the static and agitated suspension cultures. Agitated cultures allow higher gas exchange and thus permit a higher volume of cells to be cultured compared to static suspension cultures.  The benefits of in vitro production are the absence of live-animal use, although some products in the culture media come from animals; the possibility of low-serum or serum-free media production, and the absence of host-contributed immunoglobulin or antigens. One of the most common causes of failure of in vitro methods is poor adherence to basic tissue-culture techniques, such as sterilization of culture-ware, equipment, and media and humidity and temperature control in the system

• In Vivo
• In Vitro

Monoclonal Antibody Therapeutics End-user Segment Analysis

According to cognitive market research, Hospitals segment dominates the market. Due to hospitals' growing use of mAbs for cancer therapy, the hospital's category maintained the biggest market share in 2023, accounting for xx% of the total. During the projection period, factors that are projected to lead to the segment's dominance include rising healthcare expenditures globally, rising patient awareness, and the availability of advanced hospital infrastructure in developed countries. Specialty centers held a substantial portion of the market in 2021 as a result of growing government assistance in recent years. For example, the Cancer Centres Programme of the National Cancer Institute is setting guidelines for transdisciplinary cancer centers that treat, diagnose, and prevent different kinds of cancer. The growth of the segment is anticipated to be positively impacted by such activities. 

• Hospitals
• Specialty Centers
• Others

Monoclonal Antibody Therapeutics Route of Administration Segment Analysis

According to cognitive market research, Intravenoussegment dominates the market. The most common route by which mAbs are administered to patients is through intravenous (IV) infusion. The term “intravenous” means “into the vein.” During IV infusion, the diluted mAb proteins are continuously introduced through the vein into a patient’s bloodstream, where they directly interact with blood components. Since the mAbs drugs are usually prescribed in relatively high doses, a large volume of drugs can be administered safely with IV fusion. Additionally, IV infusion usually takes several hours to administer, IV fusion requires skilled personnel and hospital visits. In the case of IV infusion, the bioavailability of drugs is almost 100%. Bioavailability is defined as the fraction of an administered dose of a drug that reaches the systemic circulation. Antibodies may be administered only in settings where healthcare providers have immediate access to medications to treat any reactions and where emergency medical systems are available if needed. Intravenous infusion is strongly recommended. Subcutaneous injection is an alternative route of administration when intravenous infusion is not feasible and would lead to a delay in treatment.

• Intravenous
• Subcutaneous

Author's Detail

Ankita Sharma

Senior Research Analyst at Cognitive Market Research

LinkedIn

Profile

Ankita Sharma is a passionate and detail-driven market research professional with over 2.5 years of experience in qualitative research. With a sharp focus on client query handling and competitive intelligence, she has successfully led and delivered impactful research projects across diverse industry verticals. At the core of Ankita’s work is her ability to transform complex market data into actionable insights. She has spearheaded market intelligence initiatives by analyzing trends, evaluating competitor strategies, and mapping evolving market dynamics using a range of industry tools. Her approach combines precision with adaptability ensuring research outcomes are tailored to client-specific needs and strategic goals.
Ankita is also skilled in secondary research and product benchmarking, offering a holistic view of competitive landscapes. Her collaborative spirit and cross-functional coordination have helped refine research methodologies and maintain the highest quality standards in deliverables. Ankita’s commitment to excellence and client success makes her a valuable asset in the evolving world of market intelligence and business strategy.

Author's Conclusion